Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,985,771.69. This represents a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total transaction of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Trading Up 1.0%

Shares of NASDAQ NRIX opened at $26.04 on Wednesday. The stock has a market cap of $2.70 billion, a P/E ratio of -7.55 and a beta of 1.80. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $28.23. The business’s fifty day simple moving average is $24.65 and its 200-day simple moving average is $19.14.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. On average, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its holdings in Nurix Therapeutics by 1,598.1% during the second quarter. California State Teachers Retirement System now owns 1,681,873 shares of the company’s stock worth $40,802,000 after purchasing an additional 1,582,831 shares in the last quarter. Nykredit A S acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $32,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $341,000. Alyeska Investment Group L.P. purchased a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $3,351,000. Finally, Cookson Peirce & Co. Inc. purchased a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $558,000.

Analyst Ratings Changes

Several research firms have commented on NRIX. Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Royal Bank Of Canada raised their price objective on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Monday, August 10th. BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research note on Friday, July 10th. Jefferies Financial Group boosted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Finally, UBS Group increased their target price on Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.21.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.